All In Biotech

Drug Trial Radar · NCT03814746

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 253 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

253

Actual

Start

Jul 26, 2019

Primary completion

Aug 31, 2022

Study completion Nov 5, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.0 mg/kg and 7.5 mg/kg) versus placebo in adolescent and adult sickle cell disease (SCD) patients with history of vaso-occlusive crisis (VOC) leading to healthcare visit.

Conditions

  • Sickle Cell Disease (SCD)

Interventions

  • Crizanlizumab (SEG101)Drug

    Crizanlizumab was supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion. IV.

  • PlaceboDrug

    Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Vaso-occlusive Crisis (VOC) Events Leading to a Healthcare VisitTime frame: 1 year

Locations

58 sites in 21 countries. Site status is shown where the registry gives one.

  • Childrens Healthcare of Atlanta

    Atlanta, Georgia

  • Boston Medical Center

    Boston, Massachusetts

  • Levine Cancer Insitute Carolinas Healthcare System

    Charlotte, North Carolina

  • Univ of Tenn Health Sciences Ctr

    Memphis, Tennessee

  • U of TX Health Science Ct

    Houston, Texas

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Edegem, Belgium

  • Novartis Investigative Site

    Brussels, Brussels Capital, Belgium

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Belém, Pará, Brazil

  • Novartis Investigative Site

    Recife, Pernambuco, Brazil

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Ribeirão Preto, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Montería, Colombia

  • Novartis Investigative Site

    Barranquilla, Atlántico, Colombia

  • Novartis Investigative Site

    Valledupar, Cesar Department, Colombia

  • Novartis Investigative Site

    Helsinki, Finland

  • Novartis Investigative Site

    Créteil, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Stuttgart, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Accra, Ghana

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Pátrai, Greece

  • Novartis Investigative Site

    Thessaloniki, Greece

  • Novartis Investigative Site

    Bhubaneswar, Odisha, India

  • Novartis Investigative Site

    Hyderabad, Telangana, India

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Genova, GE, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Verona, VR, Italy

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.